4 SC Aktie - VSC

Professionelle Tools für Privatanleger.

Premium

Current Price

2,65

Gebot

2,50

Fragen

2,80

Volumen

2.245

2,40 Tagesbereich 2,74

1,82 52-Wochen-Bereich 9,50

Marktkapitalisierung

26,802M

Handelsende

2,55

Handelsbeginn

2,40

Letzte Trade

150

2.5

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

7.851

Ausgegebene Aktien

10.114.009

Dividendenrendite

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

Erlöse

345k

Nettogewinn

-8,33M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.4sc.com

Hauptsitz

Munich, Deu

Gegründet

4 SC AG is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker VSC. The last closing price for 4 SC was 2,55 €. Over the last year, 4 SC shares have traded in a share price range of 1,82 € to 9,50 €.

4 SC currently has 10.114.009 shares in issue. The market capitalisation of 4 SC is 25,79 € million.

4SC's Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat ...

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune...

4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune...

European Medicines Agency Adopts Positive Opinion for Orphan Medicinal Product Designation for 4SC's Resminostat to Treat Hep...

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune...

FDA Grants Orphan Drug Designation to 4SC's Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma

4SC AG (FWB:VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.15	6	2.5	2.74	2.4	2808	2.68	DE
4	-0.26	-8.93470790378	2.91	2.91	2.4	2852	2.69137958	DE
12	-3.07	-53.6713286713	5.72	6.2	1.82	7851	2.92664434	DE
26	-3.37	-55.9800664452	6.02	6.52	1.82	4723	3.44689072	DE
52	-5.3899999	-67.0398005851	8.0399999	9.5	1.82	3451	4.4223066	DE
156	0.68	34.5177664975	1.97	11.2	1.17	3073	4.83954522	DE
260	0.81	44.0217391304	1.84	11.2	1.17	5353	2.83246619	DE

VSC - Frequently Asked Questions (FAQ)

What is the current 4 SC share price?

The current share price of 4 SC is 2,65 €

How many 4 SC shares are in issue?

4 SC has 10.114.009 shares in issue

What is the market cap of 4 SC?

The market capitalisation of 4 SC is EUR 25,79M

What is the 1 year trading range for 4 SC share price?

4 SC has traded in the range of 1,82 € to 9,50 € during the past year

What is the reporting currency for 4 SC?

4 SC reports financial results in EUR

What is the latest annual turnover for 4 SC?

The latest annual turnover of 4 SC is EUR 345k

What is the latest annual profit for 4 SC?

The latest annual profit of 4 SC is EUR -8,33M

What is the registered address of 4 SC?

The registered address for 4 SC is FRAUNHOFERSTR. 22, PLANEGG-MARTINSRIED, MUNICH, 82152

What is the 4 SC website address?

The website address for 4 SC is www.4sc.com

Which industry sector does 4 SC operate in?

4 SC operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WW6Ww International Inc	0,3468 € (169,88%)	144,1k
OYM1Odyssey Marine Exploration Inc	1,39 € (82,89%)	120,38k
VW5Cannabist Company Holdings Inc	0,0643 € (78,61%)	153,41k
Z620Trillion Energy International Inc	0,0307 € (48,31%)	103,45k
K8DWellfield Technologies Inc	0,0142 € (47,92%)	500
A07Avance Gas Holding Ltd	0,27 € (-46,80%)	1,26M
3SHShunfeng International Clean Energy Limited	0,0014 € (-36,36%)	3k
SQRSaia Inc.	216,00 € (-30,77%)	528
L7C2Windfall Geotek Inc	0,008 € (-30,43%)	32,29k
3PJ1Golden Dory Resourses	0,02 € (-25,93%)	40k
DMLSayona Mining Limited	0,0113 € (4,63%)	2,52M
11LCanopy Growth Corporation	1,222 € (-6,86%)	2,31M
PF8European Lithium Limited	0,0314 € (3,29%)	2,18M
D7GNel ASA	0,1982 € (-1,49%)	2,15M
3CPXiaomi Corporation	5,459 € (-1,83%)	1,56M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

4 SC AG (VSC)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über 4 SC AG

VSC Neueste Nachrichten

4SC's Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat ...

4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma

European Medicines Agency Adopts Positive Opinion for Orphan Medicinal Product Designation for 4SC's Resminostat to Treat Hep...

FDA Grants Orphan Drug Designation to 4SC's Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma

4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model

4SC's Vidofludimus Inhibits IL-17 Production by Interference With the JAK/STAT and NF-B Pathways

4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat

4SC Announces Treatment of First Patient in Phase I TOPAS Study with the selective HDAC inhibitor 4SC-202

4SC Announces Financial Results 2010

VSC - Frequently Asked Questions (FAQ)

Beweger

VSC Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

4 SC AG (VSC) Börsenkurse

4 SC AG (VSC)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über 4 SC AG

VSC Neueste Nachrichten

4SC's Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat ...

4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma

European Medicines Agency Adopts Positive Opinion for Orphan Medicinal Product Designation for 4SC's Resminostat to Treat Hep...

FDA Grants Orphan Drug Designation to 4SC's Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma

4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model

4SC's Vidofludimus Inhibits IL-17 Production by Interference With the JAK/STAT and NF-B Pathways

4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat

4SC Announces Treatment of First Patient in Phase I TOPAS Study with the selective HDAC inhibitor 4SC-202

4SC Announces Financial Results 2010

VSC - Frequently Asked Questions (FAQ)

Beweger

VSC Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen